The national key R & D plan "Completely Degradable Magnesium Alloy Coronary Drug Eluting Stent R & D" 2017 Annual Summary Conference was held in Beijing on November 25, 2017.
The meeting was hosted by ZKYA Medical Technology (Beijing) Group. The project invited experts from the Ministry of Science and Technology, Pu Run and Lu Shan, and subject consultants Professor Xi Tingfei, Professor Yang Ke, and Professor Guan Shaokang to guide.
Project leader Professor Zheng Yufeng from Peking University presided over the meeting, Peking University, Fudan University, Institute of Metal Research, Chinese Academy of Sciences, ZKYA Medical Technology (Beijing) Group, TJSN Medical Science and Technology Group, Southeast University, Zhengzhou University, SZ Medical Technology Co., Ltd., SHZS Alloy The participating units of 10 topics such as Science and Technology Co., Ltd. summarized the progress of the completion of each topic in 2017. Experts of the Ministry of Science and Technology and consultant experts affirmed the achievements of the work.
In the end, the participants of the project agreed to strengthen the communication between the units in the future, and strengthen the relevance and cohesion between the tasks of the project. The fully degradable magnesium alloy coronary drug eluting stent developed by the research group is superior to the derams stent of Biotronik in Germany in terms of material performance and stent performance. I hope you will increase research and development efforts, transform scientific and technological achievements early, and serve human health.
On November 22, 2016, the national key R & D plan "Biomedical Materials R & D and Replacement of Tissues and Organs" key special project "R & D of Fully Degradable Magnesium Alloy Coronary Drug Eluting Stent" was launched, which was undertaken by TJSN Medical Science and Technology , Jointly file with Shanghai Jiaotong University, Peking University, Zhengzhou University, Fudan University and the Institute of Metal Research of the Chinese Academy of Sciences. The project will establish a complete technical system and product technical requirements for fully degradable magnesium alloy coronary drug eluting stent products with independent intellectual property rights in China, to achieve effective support of stent products in blood vessels for more than 4 months and complete degradation within 2 years. The comprehensiveness will surpass the magnesium alloy products developed by Swiss Biotronik company in clinical trials in Europe, and will reach the international advanced level.